774-41-4

Basic information

• Product Name: 2-Propanone, 1-bromo-1-(4-methoxyphenyl)-
• CAS NO: 774-41-4
• Molecular Formula: C10H11BrO2
• Molecular Weight: 243.1
• Mol File: 774-41-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Propanone, 1-bromo-1-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propanone, 1-bromo-1-(4-methoxyphenyl)-(774-41-4)
• EPA Substance Registry System: 2-Propanone, 1-bromo-1-(4-methoxyphenyl)-(774-41-4)

Safety Data

• Hazardous Substances Data: 774-41-4(Hazardous Substances Data)

Upstream product

• 50618-02-5 trans-β-methyl-4-methoxystyrene oxide 
• 3462-97-3 (4-methoxybenzyl)triphenylphosphonium bromide 
• 122-84-9 4-methoxybenzyl methyl ketone 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 20772-13-8 1-bromo-3-(4-methoxyphenyl)-2-propanone 
• 186581-53-3 diazomethane 

Downstream Products

• 1135586-56-9 1-(4-methoxyphenyl)-1-(pyrrolidin-1-yl)propan-2-one 
• 1177265-39-2 1-(4-methoxyphenyl)-1-thiocyanatopropan-2-one 
• 1025476-47-4 (Z)-ethyl 1-(4-methoxyphenyl)-2-oxopropyl 1-naphthyldithioimidocarbonate 

Relevant articles and documents

Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy

Different inflammatory diseases and allergic reactions are mediated by leukotrienes, which arise from the oxygenation of arachidonic acid catalyzed by 5-lipoxygenase (5-LO). One promising approach for an effective anti-leukotriene therapy is the inhibition of this key enzyme. This study presents the synthesis and development of a potent and direct 5-LO inhibitor based on the well characterized 5-benzylidene-2-phenylthiazolone C06, whose further pharmacological investigation was precluded due to its low solubility. Through optimization of C06, evaluation of structure-activity relationships including profound assessment of the thiazolone core and consideration of the solubility, the 5-benzyl-2-phenyl-4-hydroxythiazoles represented by 46 (ST-1829, 5-(4-chlorobenzyl)-2-p-tolylthiazol-4-ol) were developed. Compound 46 showed an improved 5-LO inhibitory activity in cell-based (ICinf50/inf values 0.141/4M) and cell-free assays (ICinf50/inf values 0.03 1/4M) as well as a prominent enhanced solubility. Furthermore, it kept its promising inhibitory potency in the presence of blood serum, excluding excessive binding to serum proteins. These facts combined with the non-cytotoxic profile mark a major step towards an effective anti-inflammatory therapy.

Highly enantioselective and diastereoselective synthesis of chiral aminoalcohols by ruthenium-catalyzed asymmetric hydrogenation of α-ami no aliphatic ketones

-